Synthorx Inc. (THOR) and Iterum Therapeutics plc (NASDAQ:ITRM) Contrasting side by side

Synthorx Inc. (NASDAQ:THOR) and Iterum Therapeutics plc (NASDAQ:ITRM) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Synthorx Inc. 15 0.00 6.11M -2.02 0.00
Iterum Therapeutics plc 3 0.00 4.99M -5.99 0.00

Table 1 highlights Synthorx Inc. and Iterum Therapeutics plc’s gross revenue, earnings per share (EPS) and valuation.


Table 2 represents Synthorx Inc. (NASDAQ:THOR) and Iterum Therapeutics plc (NASDAQ:ITRM)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Synthorx Inc. 40,924,313.46% -87.3% -61.3%
Iterum Therapeutics plc 179,257,822.32% -101.8% -76.1%


Synthorx Inc.’s Current Ratio and Quick Ratio are 22.2 and 22.2 respectively. The Current Ratio and Quick Ratio of its competitor Iterum Therapeutics plc are 4.4 and 4.4 respectively. Synthorx Inc. therefore has a better chance of paying off short and long-term obligations compared to Iterum Therapeutics plc.

Analyst Ratings

The table delivered features the ratings and recommendations for Synthorx Inc. and Iterum Therapeutics plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Synthorx Inc. 0 0 0 0.00
Iterum Therapeutics plc 0 0 1 3.00

On the other hand, Iterum Therapeutics plc’s potential upside is 518.18% and its average price target is $17.

Insider and Institutional Ownership

Roughly 86.2% of Synthorx Inc. shares are owned by institutional investors while 75.3% of Iterum Therapeutics plc are owned by institutional investors. Insiders owned 8.97% of Synthorx Inc. shares. Competitively, Iterum Therapeutics plc has 0.6% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Synthorx Inc. 6.59% 20.44% -0.72% 19.57% 0% -5.06%
Iterum Therapeutics plc 0.41% -4.8% -18.94% -2.53% -25.82% 30.74%

For the past year Synthorx Inc. has -5.06% weaker performance while Iterum Therapeutics plc has 30.74% stronger performance.


On 6 of the 10 factors Synthorx Inc. beats Iterum Therapeutics plc.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.